Acute Coronary Syndrome With Immune Checkpoint Inhibitors: A Proof-of-Concept Case and Pharmacovigilance Analysis of a Life-Threatening Adverse Event
Acute Coronary Syndrome With Immune Checkpoint Inhibitors: A Proof-of-Concept Case and Pharmacovigilance Analysis of a Life-Threatening Adverse Event
复制标题
DOI：
10.1016/j.cjca.2019.11.035
复制
发表时间：
2020-04-01
影响因子：
6.2
通讯作者：
Thuny, Franck
中科院分区：
文献类型：
--
作者：
Cautela, Jennifer;Rouby, Franck;Thuny, Franck
已经描述了与免疫检查点抑制剂（ICI）相关的急性冠状动脉综合征（ACS）孤立病例，但未建立治疗与不良事件之间的正式因果关系。我们报告了一例ACS后，第一次管理的ICI和致命的复发后，立即在另一个冠状动脉区域再次管理。根据指南，因果关系被认为是肯定的。随后，我们查询了法国药物警戒数据库，发现4例ACS伴冠状动脉血栓形成。这些患者的因果关系为“很可能相关”。这些数据表明，ACS可能是ICI暴露发生的另一种危及生命的心脏不良事件。
Isolated cases of acute coronary syndrome (ACS) associated with immune checkpoint inhibitors (ICIs) have been described without the establishment of a formal cause-and-effect relationship between treatment and adverse event. We reported a case of ACS after the first administration of an ICI and with a fatal recurrence in another coronary area immediately after readministration. According to guidelines, causality was considered to be certain. Subsequently, we queried the French pharmacovigilance database and found 4 cases of ACS with coronary artery thrombosis. Causality was probable in those patients. These data suggest that ACS may be another life-threatening cardiac adverse event occurring with ICI exposure.